Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
<p>Supplementary Table S1. Patient Characteristics.</p>
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Andere auteurs: | , , , , , , , , |
| Gepubliceerd in: |
2025
|
| Onderwerpen: | |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
| _version_ | 1849927631941664768 |
|---|---|
| author | Qingsheng Xu (17078830) |
| author2 | Kaiyuan Huang (17078833) Xiangqi Meng (17078836) Yuxiang Weng (17078839) Luyuan Zhang (17078842) Linghao Bu (17078845) Xiujue Zheng (17078848) Jinquan Cai (17078851) Renya Zhan (17078854) Qun Chen (17078857) |
| author2_role | author author author author author author author author author |
| author_facet | Qingsheng Xu (17078830) Kaiyuan Huang (17078833) Xiangqi Meng (17078836) Yuxiang Weng (17078839) Luyuan Zhang (17078842) Linghao Bu (17078845) Xiujue Zheng (17078848) Jinquan Cai (17078851) Renya Zhan (17078854) Qun Chen (17078857) |
| author_role | author |
| dc.creator.none.fl_str_mv | Qingsheng Xu (17078830) Kaiyuan Huang (17078833) Xiangqi Meng (17078836) Yuxiang Weng (17078839) Luyuan Zhang (17078842) Linghao Bu (17078845) Xiujue Zheng (17078848) Jinquan Cai (17078851) Renya Zhan (17078854) Qun Chen (17078857) |
| dc.date.none.fl_str_mv | 2025-11-25T13:30:50Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30709548 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_Table_S1_from_Safety_and_Efficacy_of_Anlotinib_Hydrochloride_Plus_Temozolomide_in_Patients_with_Recurrent_Glioblastoma/30709548 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine |
| dc.title.none.fl_str_mv | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Supplementary Table S1. Patient Characteristics.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_cc9956718f2ba4835f1f91f06a7c5690 |
| identifier_str_mv | 10.1158/1078-0432.30709548 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30709548 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent GlioblastomaQingsheng Xu (17078830)Kaiyuan Huang (17078833)Xiangqi Meng (17078836)Yuxiang Weng (17078839)Luyuan Zhang (17078842)Linghao Bu (17078845)Xiujue Zheng (17078848)Jinquan Cai (17078851)Renya Zhan (17078854)Qun Chen (17078857)CancerClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsCNS CancersGliomas, GlioblastomasPrecision Medicine<p>Supplementary Table S1. Patient Characteristics.</p>2025-11-25T13:30:50ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30709548https://figshare.com/articles/dataset/Supplementary_Table_S1_from_Safety_and_Efficacy_of_Anlotinib_Hydrochloride_Plus_Temozolomide_in_Patients_with_Recurrent_Glioblastoma/30709548CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307095482025-11-25T13:30:50Z |
| spellingShingle | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma Qingsheng Xu (17078830) Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine |
| status_str | publishedVersion |
| title | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_full | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_fullStr | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_full_unstemmed | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_short | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_sort | Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| topic | Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine |